{"ModuleTitle": "Company Description", "CompanyName": "Royalty Pharma plc", "Symbol": "RPRX", "Address": "110 EAST 59TH STREET, NEW YORK, New York, 10022, United States of America", "Phone": "(212) 883-0200", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are the largest buyer of biopharmaceutical royalties and a leading funder of\r\ninnovation across the biopharmaceutical industry. Since our founding in 1996, we\r\nhave been pioneers in the royalty market, collaborating with innovators from\r\nacademic institutions, research hospitals and not-for-profits through small and\r\nmid-cap biotechnology companies to leading global pharmaceutical companies. We\r\nhave assembled a portfolio of royalties which entitles us to payments based\r\ndirectly on the top-line sales of many of the industry's leading therapies,\r\nincluding Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri and Xtandi.\r\nWe fund innovation in the biopharmaceutical industry both directly and\r\nindirectly--directly when we partner with companies to co-fund late-stage\r\nclinical trials and new product launches in exchange for future royalties, and\r\nindirectly when we acquire existing royalties from the original innovators.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f06%2f11%2f0001193125-20-166398.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}